Ochre Bio, a company specializing in chronic liver disease treatment, has raised $30 million in series A funding.
The money will be used to develop RNA-based drug candidates from Ochre's research and imaging data of liver disease. Khosla Ventures, Hermes-Epitek, Backed VC, LifeForce Capital, Selvridge, AixThera, LifeLink and EIT along with individual investors participated in the funding round, according to the Oct. 10 Ochre news release.
"We are grateful for the support of new and existing investors, who believe in the founding premise at Ochre to marry genomics-led target discovery, human-based preclinical models, and RNA medicine to increase success rates for the development of new therapies for chronic liver disease," Ochre CEO and co-founder Jack O'Meara said. "Adding these capabilities allows us to rapidly test out new therapeutic hypotheses, and then hone in on the medicines most impactful for patients."